Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aipalolitovorelizumab + Fruquintinib in Immunodominant pMMR/MSS mCRC
NCT07229872Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in colorectal cancer (CRC), sponsored by Harbin Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07229872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229872.